Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brain quinolinic acid in Huntington's disease.

G P Reynolds1, S J Pearson, J Halket

  • 1Department of Pathology, University of Nottingham Medical School, Queen's Medical Centre, England.

Journal of Neurochemistry
|June 1, 1988
PubMed
Summary

This study measured quinolinic acid (QA), a neurotoxic metabolite, in brain tissue from Huntington's disease (HD) patients and controls. No significant differences in QA levels were found, suggesting QA does not cause neurodegeneration in HD.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MC4R methylation and antipsychotic-related metabolic changes in early psychosis: findings from two prospective cohorts.

Schizophrenia research·2026
Same author

TRACE AMINE DEFICIT IN DEPRESSIVE ILLNESS: THE PHENYLALANINE CONNEXION.

Acta psychiatrica Scandinavica·2017
Same author

Concurrent Risperidone Administration Attenuates the Development of Locomotor Sensitization Following Sub-Chronic Phencyclidine in Rats.

Pharmacopsychiatry·2016
Same author

Isatin, regional distribution in rat brain and tissues.

Neurochemistry international·2010
Same author

Brain serotonin receptors in Huntington's disease.

Neurochemistry international·2010
Same author

Schizophrenia-related endophenotypes in heterozygous neuregulin-1 'knockout' mice.

The European journal of neuroscience·2010

Area of Science:

  • Neuroscience
  • Biochemistry
  • Neurodegenerative Diseases

Background:

  • Huntington's disease (HD) is a neurodegenerative disorder.
  • Quinolinic acid (QA), a tryptophan metabolite, is implicated as a neurotoxin.

Purpose of the Study:

  • To investigate the role of quinolinic acid (QA) in Huntington's disease (HD) pathogenesis.
  • To quantify QA concentrations in postmortem brain tissue of HD patients and controls.

Main Methods:

  • Postmortem brain tissue samples from HD patients and matched controls were analyzed.
  • Gas chromatography/mass spectrometry was used to measure quinolinic acid (QA) concentrations.
  • Specific brain regions analyzed included the putamen and frontal cortex.

Main Results:

Related Experiment Videos

  • No significant differences in quinolinic acid (QA) levels were observed between Huntington's disease (HD) patients and control groups.
  • QA concentrations were comparable in the putamen and frontal cortex of both groups.

Conclusions:

  • The findings do not support the hypothesis that elevated quinolinic acid (QA) contributes to neuronal degeneration in Huntington's disease (HD).
  • Further research may be needed to elucidate the specific mechanisms of neurodegeneration in HD.